ClearPoint Neuro Reports Third Quarter 2026 Results
Stocks in this Quantisnow insightHealth Care
Historical context for CLPT
Across the 17 sessions after earlier CLPT headlines, the stock closed higher 11 times and lower 6 times, with a median move of 6.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CLPT | SPY |
|---|---|---|---|
| Oct 15, 2026 | ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 | +4.3% | +0.3% |
| Aug 4, 2026 | ClearPoint Neuro Reports Second Quarter 2026 Results | -16.3% | +1.8% |
| Aug 3, 2026 | ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel | +2.9% | +1.4% |
| Jul 22, 2026 | ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026 | -2.5% | -0.1% |
| May 28, 2026 | ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint | +6.4% | +0.6% |
| May 14, 2026 | ClearPoint Neuro Reports First Quarter 2026 Resultsand 1 other headline that session | +4.8% | +0.8% |
Quantisnow market dataNASDAQ
CLPT
ClearPoint Neuro Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
Get push alerts for CLPT
Full CLPT profile on Quantisnow Follow CLPT and get a push notification the moment its next story breaks.